TABLE 1

List of proprietary CNS compounds and marketed drugs with their physicochemical properties and fraction unbound [fu,brain (%)] in rat brain tissue homogenate (equilibrium dialysis) and TRANSIL assay

Acid/base was determined by ACD/PhysChem Suite, version 11. fu,brain (%) tissue homogenate (n = 3) and fu,brain (%) TRANSIL (n = 6) are shown as means with S.D. and CV%. Fold difference is the degree by which fu,brain (%) by equilibrium dialysis is overestimated or underestimated (in parentheses), with respect to data obtained using TRANSIL.

Drug NameMolecular MassHBA/HDBAcid/BasecLogPPSAfu,brain (%) ± S.D. Tissue HomogenateCV%fu,brain (%) ± S.D. TRANSILCV%Fold Change
GSK28392.60/2Base4.124.10.05 ± 0.01200.05 ± 0.01201
Trifluoperazine407.50/0Base4.69.70.070 ± 0.01140.180 ± 0.0056(2.6)
Thioridazine370.60/0Base5.96.50.10 ± 0.01100.030 ± 0.00133.3
GSK27424.51/2Neutral4.970.30.10 ± 0.02200.17 ± 0.013(1.7)
GSK32491.51/1Base5.735.60.11 ± 0.0190.06 ± 0.01171.8
GSK38445.53/0Neutral3.465.30.13 ± 0.0180.30 ± 0.013(2.3)
GSK30624.73/2Base2.188.30.14 ± 0.0170.20 ± 0.015(1.4)
GSK33588.62/2Base5.778.70.18 ± 0.0160.20 ± 0.015(1.1)
Chlorpromazine318.90/0Base5.26.50.20 (S)0.22 ± 0.015(1.1)
Paroxetine329.40/1Base3.739.70.39 (M)0.26 ± 0.0141.5
GSK34380.41/2Base3.973.60.44 ± 0.05110.27 ± 0.0141.6
Fluoxetine309.40/1Base3.921.30.4 ± 0.1250.30 ± 0.0131.3
GSK31616.72/0Neutral5.647.10.40 ± 0.05130.36 ± 0.0131.1
Nortriptyline263.40/1Base4120.46 (M)0.40 ± 0.0131.2
GSK10458.52/2Base2.557.30.72 ± 0.0680.42 ± 0.0121.7
Cyclobenzaprine275.40/0Base6.23.20.73 (M)1.0 ± 0.110(1.4)
Fluvoxamine318.43/1Base3.756.80.84 (M)0.74 ± 0.0571.1
Amitriptylline277.40/0Base4.43.20.9 ± 0.1110.73 ± 0.0111.2
GSK1327.43/2Neutral2.3671.00.33 ± 0.0133
GSK15378.53/2Neutral1.9741.00.70 ± 0.0571.4
GSK26378.53/2Neutral1.9741.00.70 ± 0.0341.4
Hydroxyzine3752/1Base2.335.91.02 (M)2.1 ± 0.15(2.1)
Clozapine326.90/1Neutral3.930.91.1 ± 0.190.72 ± 0.0231.5
Haloperidol375.92/1Base3.840.51.1 ± 0.191.4 ± 0.17(1.3)
GSK2370.43/2Neutral5.775.51.2 ± 0.180.81 ± 0.0111.5
GSK7355.93/1Neutral366.11.8 ± 0.161.1 ± 0.191.6
GSK18448.52/1Neutral3.567.41.8 ± 0.2112.3 ± 0.14(1.3)
GSK12382.83/1Neutral2.881.72.2 ± 0.4181.0 ± 0.1102.2
GSK24484.63/0Base3.469.42.3 ± 0.142.0 ± 0.151.2
Midazolam325.82/0Neutral3.830.22.3 ± 0.144.1 ± 0.25(1.8)
GSK11357.83/1Neutral2.577.33.0 ± 0.5171.7 ± 0.161.8
Propranolol259.41/2Base2.941.53.0 ± 0.3102.0 ± 0.151.5
GSK25363.54/1Neutral3.276.73.2 ± 0.6194.2 ± 0.25(1.3)
Diazepam284.82/0Neutral2.832.73.6 ± 0.5148.3 ± 0.45(2.3)
GSK22302.41/2Neutral2.164.43.7 ± 0.4112.0 ± 0.151.9
GW17375.62/0Zwitterion440.57.3 ± 1146.0 ± 0.47(1.2)
GSK21581.75/4Neutral1126.25.1 ± 0.8167.0 ± 0.34(1.4)
GSK3356.45/1Acid0.993.75.5 ± 0.243.7 ± 0.251.5
Trazodone371.92/0Base2.845.85.5 ± 0.6115.7 ± 0.6111
GSK35321.42/2Base2.988.16.8 ± 0.575.1 ± 0.121.3
GSK19309.51/0Base2.220.36.3 ± 0.8134.2 ± 0.121.5
GSK29402.42/0n/c4.837.67.4 ± 0.686.2 ± 0.231.2
GSK14437.63/2Base3.281.37.5 ± 0.235.8 ± 0.471.3
Phenytoin252.32/2Neutral1.458.28.1 ± 0.674.7 ± 0.241.7
GSK36448.63/0n/c4.850.59.0 ± 11112.2 ± 0.22(1.4)
Risperidone410.53/0Base2.764.29.9 ± 0.335.7 ± 0.6111.7
GSK164664/0Neutral2.463.410.5 ± 0.669.8 ± 0.771.1
GSK13362.54/3Neutral196.112 ± 21716 ± 213(1.3)
GSK8377.53/1Neutral266.111.9 ± 0.1110.2 ± 0.551.2
Carbamazepine236.31/1Neutral1.946.311.9 ± 0.7613.2 ± 0.97(1.1)
GSK23434.63/0n/c3.250.514.1 ± 21417.3 ± 0.74(1.2)
Buproprion239.81/1Neutral2.329.117 ± 31817 ± 4241
Carisoprodol260.42/2Neutral2.190.720.2 (M)29.5 ± 27(1.5)
Venlafaxine277.51/1Base2.532.721 ± 2.21012.3 ± 181.7
Buspirone385.64/0Neutral1.669.622 (M)24.0 ± 14(1.1)
GSK37416.63/0n/c3.750.523 ± 31338 ± 38(1.7)
Bupivacaine288.51/1Base3.332.327.8 ± 31117 ± 3181.6
GSK5385.55/3Neutral010931.7 ± 0.9347 ± 49(1.5)
GSK9310.34/1Neutral190.133 ± 5159.8 ± 0.553.3
GSK6385.55/3Neutral010934 ± 3939 ± 1026(1.1)
GSK4399.55/3Neutral−0.210936 ± 61721 ± 4191.7
Metoclopramide299.81/2Base2.267.636 ± 51429.5 ± 4141.2
GSK20384.53/0Zwitterion361.645 ± 61324.2 ± 0.421.9
Caffeine194.23/0Neutral−0.661.852 (M)26 ± 282
Sulpiride341.53/2Base0.8101.763 (M)24 ± 282.6
  • n/c, not calculated; (M), Maurer et al. (2005); (S), Summerfield et al. (2007).